The disease has a 100% mortality rate, but its vaccine is faked.

. The State Drug Administration announced on July 15: Recently, the State Drug Administration organized inspection teams on the basis of clues to carry out flight inspection on the production site of Changchun Changsheng Biotech Co., Ltd. The inspection team found that Changchun Changsheng in the production of freeze-dried human rabies vaccine, such as the record fraud and other serious violations of the "Drug Production Quality Management Code" (Drug GMP) behavior.Longlife biological yesterday opened to stop, the news surface, Changchun Evergreen GMP certificate was withdrawn, rabies vaccine implementation recall. By the close, the company's share price was trading at 22.10 yuan, down 9.98 percent, with 895,000 lots, or 2.4 billion yuan, on a total market value of 21.5 billion yuan. Today's opening another down, quoted 19.89 yuan.Longbiodma issued an apology and said that the problem vaccine has been fully recalled
July 16 morning, Changsheng bioannouncement said that Changchun Changsheng on the validity of all batches of freeze-dried human rabies vaccine all the implementation of the recall.
" Changchun Changsheng apologized for the incident. Changchun Changsheng will closely follow the progress of the incident, actively cooperate with the State Drug Administration, Jilin Province Food and Drug Administration and other relevant regulatory departments to carry out follow-up work, in strict accordance with the relevant provisions of the CSRC, Shenzhen Stock Exchange to fulfill the obligation of information disclosure. Investors are kindly requested to pay attention to the investment risks. The cause offraud is unknown, whether the quality of the impact has yet to be further confirmed according to the China Securities News report, Changsheng Bio Secretary Zhao Chunzhi said, "
freeze-dried human rabies vaccine sales revenue accounted for about half of Changchun's total income, this incident does not involve other vaccine products of the company, now freeze-dried man with rabies vaccine production records the specific reasons for fraud is not yet known, waiting for the results of the relevant departments."for the company's GMP certificate was withdrawn, Zhao Chunzhi said, pending the results of the investigation and rectification, the company can reapply for GMP certificate.However, "reapply ing on the GMP certificate is one or two months, and the length of six months." Dingchen Pharmaceutical Consulting Founder Shi Lichen said, because in strict accordance with the GMP requirements to produce drugs, pharmaceutical companies will be very high production costs, so caused many pharmaceutical companies in drug production, management and other aspects do not pay attention to the existence of various problems, many pharmaceutical companies have recently been revoked GMP certificate is a proof.Sina Weibo certification as The Top 10 Impact Medical V of 2016, the Vaccine and Science also tweeted to confirm the news: Changchun Changsheng Company's rabies vaccine was urgently recalled, is said to be Changchun Changsheng company reported that the company tampered with production quality data, the State Drug Administration took away all computer hosts and related personnel mobile phones.
, a well-known university of chemical engineering and technology college of pharmaceutical engineering associate professor of cat sister said that there are many kinds of production records fraud, as to whether there is an impact on product quality, need to look specifically at which aspects of fraud.
chairman of Evergreen Bio signed an emergency notice to recall the problem vaccine .On July 15th, the market received an emergency notice signed by Chairman Gao Junfang, and the company's rabies vaccine was urgently recalled.the notice requires the provincial promotion team to immediately notify the district and county disease control agencies and vaccination units in the jurisdiction, immediately stop using the company's rabies vaccine;Longlife Bio and its share of 1/4 of the freeze-dried human rabies vaccineit is understood that Changchun Evergreen Biotech Co., Ltd. is a wholly-owned subsidiary of listed company Evergreen Biotech Co., Ltd. Changchun Changsheng Biotech's official website shows that the company was founded in 1992, is engaged in human vaccine research and development, production and sales of national high-tech enterprises, in 2015 after the reorganization of assets listed.
Changsheng (002680) 2017 annual report shows that
Changchun Changsheng is china's first independent research and development and sales of influenza vaccine and human rabies vaccine (Vero cells) vaccine enterprises, is one of the few domestic companies can produce both viral vaccines and bacterial vaccines, China's first licensed cell factory technology to produce live hepatitis A vaccine.'s 2017 annual report also showed that the company's revenue was RMB1.55 billion, up 52.60 percent year-on-year, and net profit attributable to shareholders of listed companies was RMB560 million, up 33.28 percent year-on-year., vaccine sales accounted for 99.10% of revenue. By product, the proportion of category II vaccines in revenue was 91.68 percent, and the gross margin of the second-class vaccine was 90.86 percent. The wild dog vaccine (Vero cells) for freeze-dried humans is a category II vaccine and is self-funded.
long-lived biofreeze-dried humans with rabies vaccine to achieve annual revenue of more than 200 million .In 2012, the freeze-dried human rabies vaccine (Vero cell) was launched, and the first year of the vaccine was 24.683 million yuan, accounting for only 5.7% of revenue; In 2014, the vaccine's revenue quickly increased to RMB212 million, accounting for 34.36 percent of total revenue, while in the first quarter of 2015, revenue from the leaching human rabies vaccine (Vero cell) reached RMB73.789 million, accounting for about 47.1 percent.according to
statistics, in 2017, the number of rabies vaccines in Changchun was 20.78 million, accounting for 1/4 of China's market.this is not the first time Changchun Changsheng was named to informNovember 3, 2017, the former State Administration of Food and Drug Administration issued a report on the disposal of non-conforming products of the baibai-breaking vaccine price index, saying that in the drug sampling test, Changchun Evergreen Biotech Co., Ltd. produced batch number 201605014-01 of the baibai-breaking vaccine efficiency index does not meet the standard sized.in response to this matter, Longlife Bio has issued a notice that the batch of 2526 million white-break vaccine to achieve a total sales revenue of about 833.8 million yuan, in view of the baixed vaccine in the company's total sales revenue accounted for a relatively small, so the above-mentioned matters have no significant impact on the company's current production and operation.
"The batch of white-break vaccine price indicators are not qualified, may affect the effect of immunization protection, but no impact on human safety." This is the case for the effects of the hundred-white-break vaccine in this batch.rabies mortality rate of 100%rabies (rabies) is an acute infectious disease caused by rabies virus, human and animal disease, mostcommonly found in dogs, wolves, cats and other carnivores, people are infected by bites from diseased animals. Clinical manifestations are unique water-phobia, fear of wind, pharynx spasms, sexual paralysis and so on. Because of the more prominent symptoms of water-phobia, the disease is also known as hydrophobia (hydrophobia). Rabies virus belongs to the family of the virus, a single strand of RNA virus, animals through the bite of each other to spread the virus. China's rabies is mainly spread by dogs, domestic dogs can become asymptomatic carriers, so the surface of "healthy" dogs on the health of people are very harmful. For rabies is still lack of effective treatment, the fatality rate of people suffering from rabies is nearly 100%, patients generally die of respiratory or circulatory failure within 3 to 6 days, so preventive measures should be strengthened..The State Drug Administration announced on July 15: Recently, the State Drug Administration organized inspection teams on the basis of clues to the Changchun Changsheng Biotech Co., Ltd. production site flight inspection. The inspection team found that Changchun Changsheng in the production of freeze-dried human rabies vaccine, such as the record fraud and other serious violations of the "Drug Production Quality Management Code" (Drug GMP) behavior.Longlife biological yesterday opened to stop, the news surface, Changchun Evergreen GMP certificate was withdrawn, rabies vaccine implementation recall. By the close, the company's share price was trading at 22.10 yuan, down 9.98 percent, with 895,000 lots, or 2.4 billion yuan, on a total market value of 21.5 billion yuan. Today's opening another down, quoted 19.89 yuan.Longbiodma issued an apology and said that the problem vaccine has been fully recalled
July 16 morning, Changsheng bioannouncement said that Changchun Changsheng on the validity of all batches of freeze-dried human rabies vaccine all the implementation of the recall.
" Changchun Changsheng apologized for the incident. Changchun Changsheng will closely follow the progress of the incident, actively cooperate with the State Drug Administration, Jilin Province Food and Drug Administration and other relevant regulatory departments to carry out follow-up work, in strict accordance with the relevant provisions of the CSRC, Shenzhen Stock Exchange to fulfill the obligation of information disclosure. Investors are kindly requested to pay attention to the investment risks. The cause offraud is unknown, whether the quality of the impact has yet to be further confirmed according to the China Securities News report, Changsheng Bio Secretary Zhao Chunzhi said, "
freeze-dried human rabies vaccine sales revenue accounted for about half of Changchun's total income, this incident does not involve other vaccine products of the company, now freeze-dried man with rabies vaccine production records the specific reasons for fraud is not yet known, waiting for the results of the relevant departments."for the company's GMP certificate was withdrawn, Zhao Chunzhi said, pending the results of the investigation and rectification, the company can reapply for GMP certificate. However, "reapply ing on the GMP certificate is one or two months, and the length of six months." Dingchen Pharmaceutical Consulting Founder Shi Lichen said, because in strict accordance with the GMP requirements to produce drugs, pharmaceutical companies will be very high production costs, so caused many pharmaceutical companies in drug production, management and other aspects do not pay attention to the existence of various problems, many pharmaceutical companies have recently been revoked GMP certificate is a proof. Sina Weibo certification as The Top 10 Impact Medical V of 2016, the Vaccine and Science also tweeted to confirm the news: Changchun Changsheng Company's rabies vaccine was urgently recalled, is said to be Changchun Changsheng company reported that the company tampered with production quality data, the State Drug Administration took away all computer hosts and related personnel mobile phones.
, a well-known university of chemical engineering and technology college of pharmaceutical engineering associate professor of cat sister said that there are many kinds of production records fraud, as to whether there is an impact on product quality, need to look specifically at which aspects of fraud.
chairman of Evergreen Bio signed an emergency notice to recall the problem vaccine .　　On July 15th, the market received an emergency notice signed by Chairman Gao Junfang, and the company's rabies vaccine was urgently recalled. the notice requires the provincial promotion team to immediately notify the district and county disease control agencies and vaccination units in the jurisdiction, immediately stop using the company's rabies vaccine; Longlife Bio and its share of 1/4 of the freeze-dried human rabies vaccine it is understood that Changchun Evergreen Biotech Co., Ltd. is a wholly-owned subsidiary of listed company Evergreen Biotech Co., Ltd. Changchun Changsheng Biotech's official website shows that the company was founded in 1992, is engaged in human vaccine research and development, production and sales of national high-tech enterprises, in 2015 after the reorganization of assets listed.
Changsheng (002680) 2017 annual report shows that
Changchun Changsheng is china's first independent research and development and sales of influenza vaccine and human rabies vaccine (Vero cells) vaccine enterprises, is one of the few domestic companies can produce both viral vaccines and bacterial vaccines, China's first licensed cell factory technology to produce live hepatitis A vaccine. 's 2017 annual report also showed that the company's revenue was RMB1.55 billion, up 52.60 percent year-on-year, and net profit attributable to shareholders of listed companies was RMB560 million, up 33.28 percent year-on-year. , vaccine sales accounted for 99.10% of revenue. By product, the proportion of category II vaccines in revenue was 91.68 percent, and the gross margin of the second-class vaccine was 90.86 percent. The wild dog vaccine (Vero cells) for freeze-dried humans is a category II vaccine and is self-funded.
long-lived biofreeze-dried humans with rabies vaccine to achieve annual revenue of more than 200 million .　　In 2012, the freeze-dried human rabies vaccine (Vero cell) was launched, and the first year of the vaccine was 24.683 million yuan, accounting for only 5.7% of revenue; In 2014, the vaccine's revenue quickly increased to RMB212 million, accounting for 34.36 percent of total revenue, while in the first quarter of 2015, revenue from the leaching human rabies vaccine (Vero cell) reached RMB73.789 million, accounting for about 47.1 percent. according to
statistics, in 2017, the number of rabies vaccines in Changchun was 20.78 million, accounting for 1/4 of China's market. this is not the first time Changchun Changsheng was named to inform November 3, 2017, the former State Administration of Food and Drug Administration issued a report on the disposal of non-conforming products of the baibai-breaking vaccine price index, saying that in the drug sampling test, Changchun Evergreen Biotech Co., Ltd. produced batch number 201605014-01 of the baibai-breaking vaccine efficiency index does not meet the standard sized. in response to this matter, Longlife Bio has issued a notice that the batch of 2526 million white-break vaccine to achieve a total sales revenue of about 833.8 million yuan, in view of the baixed vaccine in the company's total sales revenue accounted for a relatively small, so the above-mentioned matters have no significant impact on the company's current production and operation.
"The batch of white-break vaccine price indicators are not qualified, may affect the effect of immunization protection, but no impact on human safety." This is the case for the effects of the hundred-white-break vaccine in this batch. 100% of rabies deaths in